NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212

NeOnc Technologies secured IND authorization from the Department of Health – Abu Dhabi for NEO212, marking its first international regulatory clearance and enabling clinical development outside the U.S. The company completed a Phase 1 dose-escalation study establishing 610 mg as the recommended Phase 2 dose, while its NEO100 program finished Phase 2a enrollment with data expected later this year.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.